◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › LTRN

Lantern Pharma Inc. (LTRN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

Lantern Pharma Inc. (LTRN) operates in the Biotechnology industry and is headquartered in Dallas, United States with about 16 employees. Its market capitalization is roughly $37 million. In the fiscal year ended 2025-12-31, LTRN reported $0M in revenue and ($17M) in net income.

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.

Interactive charts & full statements →

LTRN Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($18M)($22M)($18M)($14M)
Net Income($17M)($21M)($16M)($14M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LTRN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($3M)($4M)($4M)($5M)($5M)
Net Income($3M)($4M)($4M)($4M)($4M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LTRN Free Cash Flow History

LTRN Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$11M$26M$44M$59M
Total Liabilities$4M$4M$3M$3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LTRN viewer.

Other Companies in Biotechnology

← LTHAll stocksLTRX →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.